 Medical Daily |
Getting fit in middle age can reduce heart failure risk – Medical Xpress
Medical Xpress For each MET improvement in fitness, participants’ heart failure risk dropped by 20 percent. For example, if a 40-year-old went from jogging 12 minutes per mile to running 10 minutes per mile—an increase of two METs—he or she reduced heart failure … Exercise In Middle Age Could Prevent Heart FailureMedical Daily Getting Fit in Middle Age Helps Lower Risk of Heart FailureKMBZ Get Fit in Middle Age to Cut Heart Failure Risk, Study Says – NewsdayNewsday (subscription) dailyRx all 13 news articles » |
Beware of stem cell therapy claims: Column – USA TODAY
|
Beware of stem cell therapy claims: Column
USA TODAY Unfortunately, this probably will not be the only time something tragic occurs. A stem cell transplant can help cure patients with acute myeloid leukemia, and research has shown incredible potential, from growing teeth to mending “unhealable” bone … |
Darjeeling is Bengal's heart, says Mamata Banerjee – Times of India
 Calcutta Telegraph |
Darjeeling is Bengal’s heart, says Mamata Banerjee
Times of India DARJEELING: Softening her stance on GJM again on Wednesday, chief minister MamataBanerjee referred to Darjeeling as “the heart of Bengal” and went on to greet the crowd in Nepali. Soon as the CM uttered “Timi haru kasto chau (Hope you are doing … Darjeeling the heart of state: CM – The TelegraphCalcutta Telegraph Mamata Banerjee says Darjeeling an inalienable part of BengalDaily News & Analysis |
Meet the Albert Einsteins of medical jeopardy – Philly.com – Philly.com (blog)
 Philly.com (blog) |
Meet the Albert Einsteins of medical jeopardy – Philly.com
Philly.com (blog) He already did his residency in India as well,” Garrido said. “We’re a really good team. We compliment each other well. Not everybody knows everything but together we do know everything.” … he said, is enjoyable. “We’re a bunch of nerds, but we have … |
Warning didn't change for-profit dialysis drug use – Reuters
|
Warning didn’t change for-profit dialysis drug use
Reuters It’s just that it does have side effects and people do need to be aware of them,” said Dr. Nina Tolkoff-Rubin, director of renal transplantation and hemodialysis at Massachusetts General Hospital in Boston. Previous studies had found that for-profit … |
India regulators pull J&J plant license on baby powder concerns – GlobalPost – GlobalPost
India regulators pull J&J plant license on baby powder concerns – GlobalPostGlobalPostAccording to the U.S. Department of Labor, acute exposure to ethylene oxide can cause lung damage, nausea, vomiting and cancer. Ballman said the plant has not bee…
Woman who fell pregnant after undergoing world's first successful womb … – Daily Mail
 Daily Mail |
Woman who fell pregnant after undergoing world’s first successful womb …
Daily Mail Many British couples end up travelling to India, where clinics hire out women as surrogates. However, this is fraught with legal issues. For example, couples whose surrogate children are born abroad … After the first womb transplant, carried out in … |
Upcoming blood donation opportunity in Le Sueur – Southernminn.com
Upcoming blood donation opportunity in Le SueurSouthernminn.comNo matter the season, the need for blood is constant. Every two seconds someone in the U.S. needs a transfusion, and around 44,000 pints of blood must be donated every day to meet patient n…
Bristol-Myers Targets Heart-Failure Drugs in R&D Effort – Bloomberg
 Corporate Counsel |
Bristol-Myers Targets Heart-Failure Drugs in R&D Effort
Bloomberg (BMY), pouring resources into new immune system-based cancer drugs, said it also plans to expand development of treatments for congestive heart failure and fibrosis. The drugmaker also isn’t ready to give up on therapies for the neurodegenerative … Bristol-Myers Squibb Advances Leadership Position in Immuno-Oncology with …MarketWatch (press release) |
2 Scariest Dividend Stocks in Health Care – Motley Fool
|
2 Scariest Dividend Stocks in Health Care
Motley Fool Let’s assume that multiple sclerosis drug daclizumab, developed with Biogen Idec (NASDAQ: BIIB ) , gains approval. Analysts estimate peak annual sales at $500 million on the high end. AbbVie splits profits equally with Biogen, so the drug would … |